PAVmed Inc.
PAVmed Inc.'s purchase track record
PAVmed Inc. has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 10/18/2021 | LUCD | $8.00M | -56.7% | -75.9% | -2.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
PAVmed Included in List of Moving Health Care Stocks. PAVmed was featured in a Benzinga article highlighting health care stocks with notable intraday movement on Thursday. The stock is currently trading near its 52-week low, with technical indicators showing oversold conditions and a recent breakdown below support levels. This inclusion reflects current market attention to the stock's price action rather than a specific corporate announcement.
Transaction History
| LUCD | ▼ Sell | Other | 3,331,747 | — | 2/15/2024 | View on chart |
| LUCD | ▼ Sell | Other | 3,331,771 | $4.7M | 1/26/2024 | View on chart |
| PAVM | ▼ Sell | Other | 1,145,086 | $2.1M | 11/30/2022 | View on chart |
| PAVM | ▼ Sell | Other | 331,210 | $550K | 11/30/2022 | View on chart |
| PAVM | ▼ Sell | Other | 1,479,326 | $2.7M | 11/30/2022 | View on chart |
| PAVM | ▼ Sell | Other | 221,952 | $550K | 11/30/2022 | View on chart |
| PAVM | ▼ Sell | Other | 197,656 | $550K | 11/30/2022 | View on chart |
| LUCD | ▲ Buy | Open Market | 571,428 | $8.0M | 10/18/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Lucid Diagnostics Expands Payment Pathways for EsoGuard and EsoCheck
Lucid Diagnostics announced it has advanced several payment, billing, and coding pathways for its EsoGuard® and EsoCheck® products. This development could streamline reimbursement for the company’s diagnostic tests, potentially improving cash flow and market acceptance. The update follows the firm’s recent efforts to broaden its product ecosystem. Analysts maintain a target of $4.00, while the stock trades near its 52‑week low.
Lucid Diagnostics Expands Payment Pathways for EsoGuard and EsoCheck. Lucid Diagnostics announced it has advanced several payment, billing, and coding pathways for its EsoGuard® and EsoCheck® products. This development could streamline reimbursement for the company’s diagnostic tests, potentially improving cash flow and market acceptance. The update follows the firm’s recent efforts to broaden its product ecosystem. Analysts maintain a target of $4.00, while the stock trades near its 52‑week low.